Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Angina V: Nursing Management

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...

Antianginal Drugs: Nitrates and β-Blockers

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Coronary microvascular dysfunction: a narrative review.

Cardiovascular diagnosis and therapy·2026

Same author

Diagnostic accuracy of photon-counting CT for in-stent restenosis: A preliminary meta-analysis.

Journal of cardiovascular computed tomography·2026

Same author

The gut-heart axis in cardio-oncology.

Cardiovascular research·2026

Same author

Quantitative rapid image-based method for coronary artery blood flow and wall shear stress extraction.

Frontiers in bioengineering and biotechnology·2026

Same author

The asialoglycoprotein receptor 1 (ASGR1): emerging new roles in health and disease.

Biomarker research·2026

Same author

SUpporting Mothers Milk Intervention Trial (SUMMIT) - a randomised controlled trial comparing different doses of domperidone for treating lactation insufficiency in mothers of preterm infants - study protocol.

International breastfeeding journal·2026

Search research articles

Related Experiment Video

Updated: May 27, 2026

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

Cell therapy for refractory angina: time for more ACTion.

Peter J Psaltis, Robert D Simari

Stem Cell Research & Therapy

|November 11, 2011

Summary

Autologous CD34+ progenitor cell therapy significantly improved exercise tolerance and reduced angina symptoms in patients with chronic ischemic heart disease. This cell therapy offers a promising new avenue for refractory angina patients.

Area of Science:

Cardiovascular Medicine
Regenerative Medicine
Cell Therapy

Background:

Chronic ischemic heart disease presents a significant burden, necessitating advanced therapies for patients with refractory symptoms.
Existing research has primarily focused on cell therapy for myocardial infarction, with limited exploration for chronic angina.
Coronary revascularization and optimized medical therapy are often insufficient for severe, chronic ischemic conditions.

Discussion:

The ACT34-CMI trial investigated autologous peripheral blood-derived CD34+ progenitor cells for chronic ischemic heart disease.
This phase II study demonstrated significant benefits in symptom frequency and exercise capacity in patients with refractory angina.
The trial highlights the potential of cell-based approaches for treating debilitating chronic ischemic conditions.

More Related Videos

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Related Experiment Videos

Last Updated: May 27, 2026

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Key Insights:

Myocardial injection of CD34+ progenitor cells improved perfusion and vascularity in preclinical models.
Clinical application in the ACT34-CMI trial showed tangible improvements for patients with Class III and IV angina.
The study provides crucial data supporting cell therapy as a viable treatment for chronic ischemic heart disease.

Outlook:

Further research and larger trials are warranted to solidify the role of CD34+ cell therapy in cardiovascular medicine.
This approach could offer a new therapeutic strategy for patients ineligible for traditional revascularization.
Advancements in cell-based therapies hold promise for enhancing myocardial function and patient quality of life.